Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status:
Withdrawn
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well rituximab, venetoclax, and bortezomib work in treating
patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond
to treatment (refractory). Immunotherapy with monoclonal antibodies, such as rituximab, may
help the body's immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread. Venetoclax and bortezomib may stop the growth of tumor cells by
blocking some of the proteins needed for cell growth. Giving rituximab, venetoclax, and
bortezomib may slow or stop the growth of cancer cells in patients with diffuse large B-cell
lymphoma.